Feedback / Questions
ACE-232 - Acerand Therap
https://www.businesswire.com/news/home/20250603125943/en/Acerand-Therapeutics-Initiates-First-in-Human-Phase-I-Clinical-Trial-of-ACE-232-a-Novel-CYP11A1-Inhibitor-for-Advanced-Prostate-Cancer
Jun 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next